Condition

Type 2 Diabetes

Treatments and trials tagged Type 2 Diabetes. Filter by country, access level, or patient stories.

All countries United States Canada United Kingdom Japan China Australia Switzerland European Union Newest Patient Stories

FDA ApprovedUnited States European Union

Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes

Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes

Onswik (insulin efsitora alfa) is a once-weekly long-acting insulin for adults with type 2 diabetes.

This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.

September 25, 2026

Health Canada/FDA ApprovedUnited States Canada Japan China Australia Switzerland European Union

Once-Weekly Insulin Shot for Adults with Type 2 Diabetes

Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin

The first labelled once-weekly basal insulin.

Awiqli (insulin icodec) is a once-weekly long-acting insulin. The United States approved it in March 2026 only for adults with type 2 diabetes.

September 7, 2026